19BB zT2
Alternative Names: 19BB-zT2Latest Information Update: 08 Mar 2024
Price :
$50 *
At a glance
- Originator Wellington Zhaotai Therapies
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 07 Feb 2024 19BB zT2 is available for licensing as of 07 Feb 2024. https://www.wellingtonzhaotai.com/business-development
- 07 Feb 2024 Wellington Zhaotai Therapies has patent protection for CAR T-cell construct with unique, co-stimulatory domain (Wellington Zhaotai Therapies pipeline, February 2024)
- 07 Feb 2024 Preclinical trials in Lymphoma in New Zealand (Parenteral) (Wellington Zhaotai Therapies pipeline, February 2024)